Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s GPC3-armored CAR-T
Lucid Diligence Brief: AstraZeneca buys remaining China rights to AbelZeta’s…
Lucid Diligence Brief: Signet Therapeutics RMB 80 million Series A for organoids + AI in oncology
Lucid Diligence Brief: Signet Therapeutics RMB 80 million Series A for…
Lucid Diligence Brief: AstraZeneca to acquire Modella AI
Lucid Diligence Brief: AstraZeneca to acquire Modella AI Professional audiences…
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy…
Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in IBD
Lucid Diligence Brief: Caldera Therapeutics launches with $112.5 million in……
Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s deal
Lucid Diligence Brief: Novartis and SciNeuro BBB “brain-shuttle” Alzheimer’s…
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in immuno-fibrotic disease space
Lucid Diligence Brief: Mirador Therapeutics $250 million Series B in…
Lucid Diligence Brief: Aurora Therapeutics launches to scale personalized CRISPR
Lucid Diligence Brief: Aurora Therapeutics launches to scale personalized…
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4 in COPD
Lucid Diligence Brief: AirNexis Therapeutics $200 million Series A for PDE3/4…
Respiratory Today—January 9, 2026
This respiratory update spotlights reflects strong momentum across respiratory…
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A
Lucid Diligence Brief: Alveus Therapeutics $159.8 million Series A Professional…
Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences
Lucid Diligence Brief: Lilly to acquire Ventyx Biosciences Professional…